Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 7 of 21
Faron Pharma reports encouraging start to leukaemia trial
No dose-limiting toxicities or safety concerns were observed among five patients to have received the initial dose
Faron Pharma gets reiterated 'buy' rating from Peel Hunt following Bexmarilimab therapy news
The City broker's analysts said: "We already knew that data was promising across all the indication areas (eg the recent top-line data on Bexmarilimab dose variation), and this news today is an incremental positive"
Faron Pharma's cancer treatment has the capacity to ignite immunity in people with late-stage skin cancer
The company's MATINS study is assessing how its promising cancer drug, bexmarilimab, performs in 10 treatment-resistant tumour types. The data below is from the melanoma group
Faron Pharma: Broker reiterates 'buy' and price target after accelerated fundraiser
Peel Hunt, the company's corporate broker, reckons the stock is worth 524p
Faron Pharma says cancer programme to be fast tracked after successful €8mln fundraiser
Bexmarilimab has shown promise in an early-stage clinical trial
Faron Pharmaceuticals hails potential of cancer immunotherapy as it updates early-phase trial data
The survival rate of those taking bexmarilimab was almost 15 months - significantly higher than those not receiving the treatment
Faron Pharma says study points to the promise of its drug in emergency and trauma patients
Data from the study will be presented at the Military Health System Research Symposium
Faron Pharma to accelerate clinical development of cancer treatment Bexmarilimab
A study showed 100% of checkpoint refractory skin cancer and bile duct cancer patients treated with Bexmarilimab survived for a year
Faron Pharma raises €5mln; brings in leading charity as an investor
The fundraiser won the backing of the Leukemia & Lymphoma Society Therapy Acceleration Program
Faron Pharma encouraged by survival rates in latest MATINS trial data
Faron said the strongest survival benefit was seen in refractory skin cancer and bile duct cancer.
Faron Pharmaceuticals doses first patient in bexmarilimab combination study
The trial marks the first time the company's bexmarilimab immunotherapy asset is being assessed as part of a clinical study in hematologic malignancies
Faron Pharma to showcase the potential of cancer drug at ASCO conference
Drawing on work carried out via its MATINS trial, the American Society of Clinical Oncology will be given a number of data insights